Publications

Cancer immunology, immunotherapy : CII

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.

01-05-2019

Virchows Archiv : an international journal of pathology

Adoptive cellular therapies: the current landscape.

01-04-2019

Nature medicine

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy.

01-04-2019

The New England journal of medicine

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

21-03-2019

Cancer immunology, immunotherapy : CII

The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.

01-03-2019

Oncoimmunology

A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma.

07-02-2019

Cell

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma.

07-02-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

01-02-2019

JAMA oncology

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

01-02-2019

Cancer immunology, immunotherapy : CII

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.

01-02-2019

Cancer immunology research

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.

01-01-2019

Journal of biotechnology

Small-scale GMP production of plasmid DNA using a simplified and fully disposable production method.

01-01-2019

Nature medicine

Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers.

01-01-2019

Cancer immunology research

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.

01-01-2019

The Lancet. Haematology

Characterisation of rare haematological immune-related toxicities.

01-01-2019

Cell

NKG2A, a New Kid on the Immune Checkpoint Block.

13-12-2018

The New England journal of medicine

Sunitinib Alone or after Nephrectomy in Renal Cancer.

08-11-2018

Nature medicine

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

01-11-2018

Annals of oncology : official journal of the European Society for Medical Oncology

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).

01-11-2018

Journal of immunotherapy (Hagerstown, Md. : 1997)

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product.

10-10-2018

Journal for immunotherapy of cancer

Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.

03-10-2018

ESMO open

Report on the status of women occupying leadership roles in oncology.

03-10-2018

ESMO open

Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey.

03-10-2018

Nature reviews. Clinical oncology

Cytoreductive nephrectomy in metastatic renal cancer - less is more.

01-10-2018

BMC cancer

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation.

15-09-2018

Cell

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.

06-09-2018

Melanoma research

Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.

01-08-2018

ESMO open

Questions asked in the everyday practice: immune checkpoint inhibitors.

19-07-2018

Anti-cancer drugs

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.

01-07-2018

Anti-cancer drugs

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.

01-07-2018

Nederlands tijdschrift voor geneeskunde

[Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry].

15-06-2018

American journal of clinical dermatology

Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.

01-06-2018

Melanoma research

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.

01-04-2018

ESMO open

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.

02-02-2018

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Pembrolizumab in Small-Cell Lung Cancer: In Search of the Best Biomarker.

01-12-2017

Urology

Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma.

01-11-2017

The New England journal of medicine

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

05-10-2017

Annals of oncology : official journal of the European Society for Medical Oncology

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.

01-10-2017

The oncologist

Fixed Dosing of Monoclonal Antibodies in Oncology.

01-10-2017

BMC cancer

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.

15-09-2017

Cell

Converting Cold into Hot Tumors by Combining Immunotherapies.

07-09-2017

Cancer immunology, immunotherapy : CII

HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia.

01-09-2017

European journal of cancer (Oxford, England : 1990)

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

01-09-2017

Ocular oncology and pathology

Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma.

01-09-2017

Annals of oncology : official journal of the European Society for Medical Oncology

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

01-07-2017

Annals of oncology : official journal of the European Society for Medical Oncology

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

01-07-2017

Angiogenesis

Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.

01-05-2017

JAMA oncology

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.

01-04-2017

Annals of oncology : official journal of the European Society for Medical Oncology

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience.

01-04-2017

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

(Neo)adjuvant systemic therapy for melanoma.

01-03-2017